DDAffinity: predicting the changes in binding affinity of multiple point mutations using protein 3D structure
Bioinformatics · 28.06.2024 · 40 (Supplement_1) · i418-i427
DOI: 10.1093/bioinformatics/btae232 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioinformatics, online erschienen am 28.06.2024. Verfasst von Guanglei Yu und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Computer Science and Engineering, Central South University, Changsha 410083, China. Hauptthemen laut MEDLINE: Point Mutation, SARS-CoV-2. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Science Foundation for Distinguished Young Scholars of Hunan Province, High Performance Computing Center of Central South University.
Abstract (Originalsprache)
Motivation Mutations are the crucial driving force for biological evolution as they can disrupt protein stability and protein–protein interactions which have notable impacts on protein structure, function, and expression. However, existing computational methods for protein mutation effects prediction are generally limited to single point mutations with global dependencies, and do not systematically take into account the local and global synergistic epistasis inherent in multiple point mutations. Results To this end, we propose a novel spatial and sequential message passing neural network, named DDAffinity, to predict the changes in binding affinity caused by multiple point mutations based on protein 3D structures. Specifically, instead of being on the whole protein, we perform message passing on the k-nearest neighbor residue graphs to extract pocket features of the protein 3D structures. Furthermore, to learn global topological features, a two-step additive Gaussian noising strategy during training is applied to blur out local details of protein geometry. We evaluate DDAffinity on benchmark datasets and external validation datasets. Overall, the predictive performance of DDAffinity is significantly improved compared with state-of-the-art baselines on multiple point mutations, including end-to-end and pre-training based methods. The ablation studies indicate the reasonable design of all components of DDAffinity. In addition, applications in nonredundant blind testing, predicting mutation effects of SARS-CoV-2 RBD variants, and optimizing human antibody against SARS-CoV-2 illustrate the effectiveness of DDAffinity. Availability and implementation DDAffinity is available at https://github.com/ak422/DDAffinity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Computer Science and Engineering, Central South University, Changsha 410083, China.
- Hunan Provincial Key Lab on Bioinformatics, Central South University, Changsha 410083, China.
- Medical Engineering and Technology College, Xinjiang Medical University, Urumqi 830017, China.
ORCID-Profile: Qichang Zhao, Jianxin Wang
Förderung
- National Natural Science Foundation of China
- Science Foundation for Distinguished Young Scholars of Hunan Province
- High Performance Computing Center of Central South University
Zitieren
APA
Yu, G., Zhao, Q., Bi, X., & Wang, J. (2024). DDAffinity: predicting the changes in binding affinity of multiple point mutations using protein 3D structure. Bioinformatics, 40(Supplement_1), i418-i427. https://doi.org/10.1093/bioinformatics/btae232
Vancouver
Yu G, Zhao Q, Bi X, Wang J. DDAffinity: predicting the changes in binding affinity of multiple point mutations using protein 3D structure. Bioinformatics. 2024;40(Supplement_1):i418-i427. doi:10.1093/bioinformatics/btae232
BibTeX
@article{Yu2024,
author = {Yu, Guanglei and Zhao, Qichang and Bi, Xuehua and Wang, Jianxin},
title = {DDAffinity: predicting the changes in binding affinity of multiple point mutations using protein 3D structure},
journal = {Bioinformatics},
year = {2024},
volume = {40},
number = {Supplement_1},
pages = {i418--i427},
doi = {10.1093/bioinformatics/btae232}
}
EUVIMED